Adenosine Generated in the Bone Marrow Niche Through a CD38-Mediated Pathway Correlates With Progression of Human Myeloma

Adenosine Generated in the Bone Marrow Niche Through a CD38-Mediated Pathway Correlates With Progression of Human Myeloma

Abstract Human myeloma cells express CD38 at high levels and grow in hypoxic niches inside the bone marrow. Myeloma cells respond to hypoxia with metabolic changes leading to aerobic glycolysis, thus reducing adenosine triphosphate (ATP) and increasing NAD+. Our hypothesis is that these conditions f...

Full description

Bibliographic Details
Main Authors:	Alberto L Horenstein, Valeria Quarona, Denise Toscani, Federica Costa, Antonella Chillemi, Vito Pistoia, Nicola Giuliani, Fabio Malavasi
Format:	Article
Language:	English
Published:	BMC 2016-10-01
Series:	Molecular Medicine
Online Access:	http://link.springer.com/article/10.2119/molmed.2016.00198

Similar Items

CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma
by: Fabio Morandi, et al.
Published: (2018-11-01)

Cytokine-Induced Killer Cells Express CD39, CD38, CD203a, CD73 Ectoenzymes and P1 Adenosinergic Receptors
by: Alberto L. Horenstein, et al.
Published: (2018-04-01)

NAD+-Metabolizing Ectoenzymes in Remodeling Tumor–Host Interactions: The Human Myeloma Model
by: Alberto L. Horenstein, et al.
Published: (2015-09-01)

CD38 in Adenosinergic Pathways and Metabolic Re-programming in Human Multiple Myeloma Cells: In-tandem Insights From Basic Science to Therapy
by: Alberto L. Horenstein, et al.
Published: (2019-04-01)

PD-L1/PD-1 Axis in Multiple Myeloma Microenvironment and a Possible Link with CD38-Mediated Immune-Suppression
by: Federica Costa, et al.
Published: (2021-01-01)

Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD+
by: F. Morandi, et al.
Published: (2018-08-01)

Editorial: Immunotherapy in Multiple Myeloma
by: Nicola Giuliani, et al.
Published: (2019-08-01)

The Circular Life of Human CD38: From Basic Science to Clinics and Back
by: Alberto L. Horenstein, et al.
Published: (2020-10-01)

Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model
by: Beatrice Anna Zannetti, et al.
Published: (2020-12-01)

CD73/Adenosine Pathway Involvement in the Interaction of Non-Small Cell Lung Cancer Stem Cells and Bone Cells in the Pre-Metastatic Niche
by: Belisario, D.C, et al.
Published: (2022)

PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients
by: Federica Costa, et al.
Published: (2021-01-01)

Actors on the Scene: Immune Cells in the Myeloma Niche
by: Patrizia Leone, et al.
Published: (2020-10-01)

Double CD38−/CD138− negative multiple myeloma
by: Vitaliy Mykytiv, et al.
Published: (2019-03-01)

The Role of Proteasome Inhibitors in Multiple Myeloma Bone Disease and Bone Metastasis: Effects on Osteoblasts and Osteocytes
by: Denise Toscani, et al.
Published: (2021-05-01)

CD38 Ligation in Peripheral Blood Mononuclear Cells of Myeloma Patients Induces Release of Protumorigenic IL-6 and Impaired Secretion of IFNγ Cytokines and Proliferation
by: Giorgio Fedele, et al.
Published: (2013-01-01)

Bone Marrow CX3CL1/Fractalkine is a New Player of the Pro-Angiogenic Microenvironment in Multiple Myeloma Patients
by: Valentina Marchica, et al.
Published: (2019-03-01)

Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?
by: Torben Plesner, et al.
Published: (2020-02-01)

The Role of Extracellular Adenosine Generation in the Development of Autoimmune Diseases
by: F. Morandi, et al.
Published: (2018-01-01)

Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma
by: Ilaria Saltarella, et al.
Published: (2020-01-01)

CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond
by: Dario Roccatello, et al.
Published: (2020-06-01)

Daratumumab induces CD38 internalization and impairs myeloma cell adhesion
by: Jayeeta Ghose, et al.
Published: (2018-10-01)

CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance
by: Niels W.C.J. van de Donk, et al.
Published: (2018-09-01)

Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling
by: Fabrizio Accardi, et al.
Published: (2015-01-01)

Role of Osteocytes in Myeloma Bone Disease: Anti-sclerostin Antibody as New Therapeutic Strategy
by: Denise Toscani, et al.
Published: (2018-10-01)

Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade
by: Samah Elsaadi, et al.
Published: (2020-06-01)

Eosinophils and megakaryocytes support the early growth of murine MOPC315 myeloma cells in their bone marrow niches.
by: David Wong, et al.
Published: (2014-01-01)

Cellular immunotherapy on primary multiple myeloma expanded in a 3D bone marrow niche model
by: Maaike V. J. Braham, et al.
Published: (2018-06-01)

Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche
by: Victoria Jennings, et al.
Published: (2021-03-01)

Resistance Mechanisms Towards CD38−Directed Antibody Therapy in Multiple Myeloma
by: Laurens E. Franssen, et al.
Published: (2020-04-01)

In vivo evaluation of CD38 and CD138 as targets for nanoparticle-based drug delivery in multiple myeloma
by: David T. Omstead, et al.
Published: (2020-11-01)

Novel Approaches to Improve Myeloma Cell Killing by Monoclonal Antibodies
by: Paola Storti, et al.
Published: (2020-09-01)

Bone Marrow Mesenchymal Stromal Cell-mediated Resistance in Multiple Myeloma Against NK Cells can be Overcome by Introduction of CD38-CAR or TRAIL-variant
by: Lisa C. Holthof, et al.
Published: (2021-05-01)

Perspectives for the Development of CD38-Specific Heavy Chain Antibodies as Therapeutics for Multiple Myeloma
by: Peter Bannas, et al.
Published: (2018-11-01)

CD38-targeted therapy with daratumumab reduces autoantibody levels in multiple myeloma patients
by: Kristine A. Frerichs, et al.
Published: (2019-12-01)

Expression and clinical significance of CD38 and multiple myeloma oncogene 1 in autoimmune hepatitis
by: JIANG Lilin
Published: (2019-09-01)

Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma
by: Larysa Sanchez, et al.
Published: (2016-06-01)

Myeloma Cells Deplete Bone Marrow Glutamine and Inhibit Osteoblast Differentiation Limiting Asparagine Availability
by: Martina Chiu, et al.
Published: (2020-11-01)

Microvesicles expressing adenosinergic ectoenzymes and their potential role in modulating bone marrow infiltration by neuroblastoma cells
by: Fabio Morandi, et al.
Published: (2019-05-01)

Oncolytic Virotherapy and Microenvironment in Multiple Myeloma
by: Valentina Marchica, et al.
Published: (2021-02-01)

Differential Function of a Novel Population of the CD19+CD24hiCD38hi Bregs in Psoriasis and Multiple Myeloma
by: Joanna Bartosińska, et al.
Published: (2021-02-01)